pain therapy market

chronic pain

An illustration of a brain

The pain therapy market » Chronic pain

What is neuropatic pain?

Pain is a negative feeling associated with damage to the body’s tissues and is crucial to survival. Sometimes damage to the tissues from trauma or some diseases, for example, viral infection, shingles and diabetes, results in neuropathic pain that does not resolve, and the pain becomes chronic. This has no survival value and, indeed, results in a real reduction in sufferers’ quality of life.

Focus on allodynia

PharmNovo initially focuses on neuropathic pain with allodynia. Allodynia is a distressing part of neuropathic pain states. It is pain on the skin from something that shouldn’t be painful. This makes simple day-to-day activities, such as getting dressed, very unpleasant, and this has a negative impact on sufferers’ quality of life.

Allodynia is common in neuropathic pain states such as shingles, diabetic neuropathy, physical injury to nerves and migraine. Existing treatments are largely ineffective, but the drug candidate PN6047 from PharmNovo, blocks allodynia in animal models, and its potential in the human condition is clear.

The drug candidate is being developed for neuropathic pain in general, but by focusing  the study on peripheral nerve pain with mechanical allodynia, a semi-quantitative way of measuring effect can be used, which increases the likelihood of demonstrating efficacy.

NEUROPATHIC PAIN POINTS

  • Neuropathic pain, occurs when a health condition affects the nerves that carry sensations to your brain.
  • Neuropathic pain is characterized by excessive sensitivity to stimuli, including allodyniaa condition in which pain is caused by a stimulus that does not usually elicit pain and hyperalgesia in which pain is exaggerated.
  • Neuropathic pain is caused by damage or disease affecting the sensory system. About 30% of all neuropathic pain happens because of diabetes.
  • Neuropathic pain is usually chronic; the body just sends pain signals to your brain unprompted. Neuropathic pain tends to get worse over time.
  • Most of the available treatments for neuropathic pain have only moderate efficacy and produce side effects that limit their use; therefore, there is a great need for new therapeutic approaches.
An illustration of a man having arm pain with arrows pointing to the brain

Latest news

View all
June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.

Read more
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more
January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more